CRISPR Therapeutics Stock News

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD,

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies a

Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge

Cathie Wood is as bullish as ever, but recent economic indicators point to strength for her favorite stocks. In an interview, Cathie Wood emphasized that deflation is now a key concern rather than inf

CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.

Shares of Crispr Therapeutics CRSP, +1.68% and Vertex Pharmaceuticals Inc. VRTX, -5.57% gained ground premarket on Thursday after the companies got the world's first regulatory authorization for a med

CRISPR Therapeutics (NASDAQ: CRSP ) stock rose 5% on news the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It's the first authorization in the world for the CR

CRISPR Therapeutics shares have advanced this year, but they're still far from their peak. The company is heading for its biggest moment ever: potential product approval.

One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

Growth stocks could lead this latest market rally -- and may deliver growth to your portfolio over time. Amazon and CRISPR Therapeutics are well positioned to benefit from the next bull market.

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr

CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.